Rho-dependent, Rho kinase-independent inhibitory regulation of Rac and cell migration by LPA1 receptor in Gi-inactivated CHO cells

N Sugimoto, N Takuwa, K Yoshioka… - Experimental cell research, 2006 - Elsevier
N Sugimoto, N Takuwa, K Yoshioka, Y Takuwa
Experimental cell research, 2006Elsevier
Lysophosphatidic acid (LPA) is a major serum lysophospholipid that stimulates cell
migration in diverse cell types including ovarian cancer cells. We report here that in the
absence of Gi function, LPA induces inhibition, rather than stimulation, of cellular Rac
activity, lamellipodium formation, and cell migration in response to insulin like growth factor I
(IGF-I) in Chinese hamster ovary (CHO) cells, which solely express LPA1 as a LPA receptor.
The inhibitory effects of LPA are abrogated by the expression of either Gα13 C-terminal …
Lysophosphatidic acid (LPA) is a major serum lysophospholipid that stimulates cell migration in diverse cell types including ovarian cancer cells. We report here that in the absence of Gi function, LPA induces inhibition, rather than stimulation, of cellular Rac activity, lamellipodium formation, and cell migration in response to insulin like growth factor I (IGF-I) in Chinese hamster ovary (CHO) cells, which solely express LPA1 as a LPA receptor. The inhibitory effects of LPA are abrogated by the expression of either Gα13 C-terminal peptide or C3 toxin pretreatment, but not a Rho kinase inhibitor. Without PTX pretreatment, LPA stimulates Rac and cell migration yet similarly activates Rho, indicating that Rho activation by itself is not sufficient for inhibition of cell migration. Conversely, the expression of a dominant negative Rac mutant sufficiently mimics the LPA inhibition of cell migration. LPA inhibits IGF I-induced Akt activation by only 40% in a manner dependent on Rho kinase. These results demonstrate that inhibition of Gi function converts LPA regulation on Rac and cell migration to an inhibitory mode, which is mediated by G13 and Rho but not Rho kinase, and raise a possibility of Gi as a new therapeutic target for LPA-dependent tumor progression.
Elsevier